Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment

Lung, Respiratory and Thoracic Cancer

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Lung Cancer

Zhang Q, Yang Y, Xie M, Zhou Z, Wu H, Zhai W, Chen Y, Chen K, Zhou S, Li H, Fan Y

doi: 10.1016/j.lungcan.2025.108616

Lung, Respiratory and Thoracic Cancer

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Lung Cancer

Eklund EA, Orgard M, Wallin D, Sayin SI, Fagman H, Isaksson J, Raghavan S, Akyürek LM, Nyman J, Wiel C, Hallqvist A, Sayin VI

doi: 10.1016/j.lungcan.2025.108573

Lung, Respiratory and Thoracic Cancer

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Lung Cancer

Huijs JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, Bensch F, Hijmering-Kappelle LBM, de Schrevel TMT, van Geffen WH, Youssef-El Soud M, Steens MMH, Pitz C, De Ruysscher DKM, Hendriks LEL

doi: 10.1016/j.lungcan.2025.108745

Further Publications

Neurocognitive outcomes in patients with brain metastases: a systematic review

Lancet Oncol

Bou Dargham T, Winter SF, Batich K, Gehring K, Parsons MW, Dietrich J, Mullikin T, Reitman ZJ, Floyd SR, Kirkpatrick JP, Sperduto PW, Hattangadi-Gluth J, Shih HA, Brown PD, Mehta M, Sulman EP, Peters KB, Vaios EJ

doi: 10.1016/S1470-2045(25)00525-X

Further Publications

Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis

JAMA Oncol

Huang RS, Chen D, Benour A, Cortez R, Mihalache A, Johnny C, Bezjak A, Olson RA, Raman S

doi: 10.1001/jamaoncol.2025.3153

Lung, Respiratory and Thoracic Cancer

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation

Lung Cancer

Faehling M, Fallscheer S, Schmiederer J, Sträter J, Christopoulos P, Lengerke C, Seifarth H

doi: 10.1016/j.lungcan.2025.108803

Lung, Respiratory and Thoracic Cancer

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Lung Cancer

Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermiş E, Wagner F, Früh M, Schmid S

doi: 10.1016/j.lungcan.2025.108813

Skin Cancer

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Lancet Oncol

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D

doi: 10.1016/S1470-2045(25)00139-1

Skin Cancer

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study

Eur J Cancer

Mandalà M, Amaral T, Rutkowski P, Sergi MC, Rasch ML, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Dirven I, Tucci M, Guida M, Spagnolo F, Rossi E, Queirolo P, Quaglino P, Depenni R, Placzke J, Giacomo AMD, Del Vecchio M, Indini A, Silva IPD, Menzies AM, Hong A, Lorigan P, Long GV, Robert C, Ascierto PA

doi: 10.1016/j.ejca.2025.115567

Related content

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Neurocognitive outcomes in patients with brain metastases: a systematic review

Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer: A Systematic Review and Meta-Analysis

Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study